Jim Cramer on Pfizer: “I Would Hold on to It”

Core Viewpoint - Pfizer Inc. is viewed as a stock with potential growth opportunities, particularly with upcoming developments expected to be discussed at the JPMorgan conference in January 2024, while also providing a substantial dividend yield of approximately 6.8% to 6.9% [1][2]. Group 1: Company Overview - Pfizer Inc. develops and sells medicines and vaccines for various health conditions, including heart disease, infections, COVID-19, and rare diseases [2]. - The company has faced challenges with share price appreciation, leading to its characterization as a bond equivalent due to its high yield [2]. Group 2: Investment Potential - The stock is considered controversial due to its stagnant share price, but the high yield offers a decent return even if the stock does not appreciate significantly [2]. - Pfizer has the potential to leverage its recent acquisitions to build a strong pipeline that could mitigate concerns over patent expirations [2].